GlycoMimetics is focused on discovering and developing novel medicines based on an understanding of the roles carbohydrates play in health and disease. All of GlycoMimetics’ compounds have been generated internally, leveraging the company’s specialized chemistry and our in-depth understanding of carbohydrate biology (“glycobiology”).
GMI-1070, the lead candidate within our clinical portfolio, has the potential to provide a treatment for vaso-occlusive crisis of sickle cell disease, one of the most common genetic diseases in the United States. Our pipeline also includes: